JP2025500288A5 - - Google Patents

Info

Publication number
JP2025500288A5
JP2025500288A5 JP2024536366A JP2024536366A JP2025500288A5 JP 2025500288 A5 JP2025500288 A5 JP 2025500288A5 JP 2024536366 A JP2024536366 A JP 2024536366A JP 2024536366 A JP2024536366 A JP 2024536366A JP 2025500288 A5 JP2025500288 A5 JP 2025500288A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
sequence number
chain variable
variable domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024536366A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025500288A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/087829 external-priority patent/WO2023118608A1/en
Publication of JP2025500288A publication Critical patent/JP2025500288A/ja
Publication of JP2025500288A5 publication Critical patent/JP2025500288A5/ja
Pending legal-status Critical Current

Links

JP2024536366A 2021-12-23 2022-12-23 細胞療法に使用するためのcd45の識別可能な細胞表面タンパク質変異体 Pending JP2025500288A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21217465.0 2021-12-23
EP21217465 2021-12-23
PCT/EP2022/087829 WO2023118608A1 (en) 2021-12-23 2022-12-23 Discernible cell surface protein variants of cd45 for use in cell therapy

Publications (2)

Publication Number Publication Date
JP2025500288A JP2025500288A (ja) 2025-01-09
JP2025500288A5 true JP2025500288A5 (cg-RX-API-DMAC7.html) 2026-01-06

Family

ID=79171049

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024536366A Pending JP2025500288A (ja) 2021-12-23 2022-12-23 細胞療法に使用するためのcd45の識別可能な細胞表面タンパク質変異体

Country Status (10)

Country Link
EP (1) EP4452417A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025500288A (cg-RX-API-DMAC7.html)
KR (1) KR20240119146A (cg-RX-API-DMAC7.html)
CN (1) CN118541158A (cg-RX-API-DMAC7.html)
AU (1) AU2022422572A1 (cg-RX-API-DMAC7.html)
CA (1) CA3240875A1 (cg-RX-API-DMAC7.html)
IL (1) IL313785A (cg-RX-API-DMAC7.html)
MX (1) MX2024007316A (cg-RX-API-DMAC7.html)
WO (1) WO2023118608A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202405124B (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3110837A1 (en) 2018-08-28 2020-03-05 Vor Biopharma Inc. Genetically engineered hematopoietic stem cells and uses thereof
WO2026082736A1 (en) * 2024-10-14 2026-04-23 Cimeio Therapeutics Ag Chimeric antigen receptor (car) that targets receptor-type tyrosine phosphatase c (cd45) and its use to related applications

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170226209A1 (en) 2014-08-01 2017-08-10 INSERM (Institut National de la Santé et de la Recherche Médicale) An anti-cd45rc antibody for use as drug
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
CA3016901C (en) 2016-03-07 2023-06-13 Actinium Pharmaceuticals, Inc. Stabilized radiolabeled anti-cd45 immunoglobulin compositions
EP3448995A1 (en) 2016-04-25 2019-03-06 Universität Basel Allele editing and applications thereof
CN109641051A (zh) 2016-06-17 2019-04-16 美真达治疗公司 用于耗尽细胞的组合物和方法
US20190365806A1 (en) 2016-11-02 2019-12-05 Universität Basel Immunologically discernible cell surface variants for use in cell therapy
KR102709603B1 (ko) 2017-02-28 2024-09-27 보르 바이오파마 인크. 계통 특이적 단백질의 억제를 위한 조성물 및 방법
CA3078963A1 (en) 2017-10-25 2019-05-02 Actinium Pharmaceuticals, Inc. Anti-cd45-based conditioning methods and uses thereof in conjunction with gene-edited cell-based therapies
EP3498293A1 (en) 2017-12-15 2019-06-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Treatment of monogenic diseases with an anti-cd45rc antibody
CN109991410B (zh) 2017-12-29 2022-07-05 上海白泽医学检验所有限公司 一种含抗cd45单抗的组合物及其使用方法
US20210269526A1 (en) 2018-07-16 2021-09-02 Fred Hutchinson Cancer Research Center Bispecific affinity reagent and related methods for pretargeted radioimmunotherapy against cd45+ cell
EP3626265A1 (en) 2018-09-21 2020-03-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-human cd45rc antibodies and uses thereof
AU2019374055B2 (en) * 2018-10-30 2026-06-11 Regeneron Pharmaceuticals, Inc. Methods for allogeneic hematopoietic stem cell transplantation
AU2019370367A1 (en) 2018-10-30 2021-06-17 Magenta Therapeutics, Inc. Anti-CD45 antibodies and conjugates thereof
EP3917313A4 (en) 2019-02-01 2023-02-08 Actinium Pharmaceuticals, Inc. MOLECULES AND THEIR DERIVATIVES AGAINST CD45
EP3927361A4 (en) 2019-02-21 2022-11-30 Ramot at Tel-Aviv University Ltd. TREATMENT OF DISEASES WITH MULTIMERIC PEPTIDES

Similar Documents

Publication Publication Date Title
JP7462621B2 (ja) 三重特異性抗cd38、抗cd28、および抗cd3結合タンパク質ならびにウイルス感染を処置するための使用方法
JP6731403B2 (ja) 免疫応答およびがん治療の増強に使用するための組成物および方法
US20210024631A1 (en) Bi-functional proteins and construction thereof
KR102910874B1 (ko) 구획, 특히 cns로의 국소 전달을 위한 fc 변형 생물학적 제제
CN107074951B (zh) 拮抗性抗-ox40l抗体及其使用方法
TW202112824A (zh) 進一步與mhc分子結合的募集因子
CN114341189A (zh) 全新il-15前药及其应用
JP2019527543A5 (cg-RX-API-DMAC7.html)
JP2022521937A5 (cg-RX-API-DMAC7.html)
EP3833391A1 (en) SIRP1alpha TARGETED CHIMERIC PROTEINS AND USES THEREOF
JP2021529796A (ja) 多特異性Wnt代替分子及びその使用
TW200902547A (en) Potent, stable and non-immunosuppressive anti-CD4 antibodies
JP2023123763A (ja) Uti融合タンパク質
CN114736291B (zh) 特异性结合发热伴血小板减少综合征病毒的囊膜蛋白Gn的人源单克隆抗体及其用途
JP2024546996A5 (cg-RX-API-DMAC7.html)
TW202607029A (zh) 三特異性結合蛋白、方法及其用途
JP2022532274A (ja) ヒトtrbv9のベータ鎖領域に対するモノクローナル抗体
US11926676B2 (en) Masked chimeric antigen receptor specific to tyrosine-protein kinase like 7 (PTK7) and immune cells expressing such
TW201008580A (en) Dual variable domain immunoglobulin and uses thereof
CN118451096A (zh) 异二聚体fc细胞因子及其用途
JP2022500042A (ja) 抗hiv抗体10−1074バリアント
CN106459186A (zh) 针对hiv‑1 v1v2 env区域的广谱中和性单克隆抗体
US20180111991A1 (en) Modulators of activin and methods for modulating immune responses and t follicular helper cells
JP2021527429A (ja) 造血幹細胞を除去するための抗体薬物コンジュゲート
JP7127859B2 (ja) キメラタンパク質を用いたアレルギー疾患の治療